FA
HALO icon

Faithward Advisors’s Halozyme HALO Stock Holding History

Faithward Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Sell
25,249
-38,154
-60% -$2.6M 0.24% 104
2026
Q1 		$5.24M Buy
63,403
+40,333
+175% +$2.84M 0.75% 37
2025
Q4 		$1.55M Buy
+23,070
New +$1.55M 0.23% 95

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Faithward Advisors's HALO Position: Q2 2026 in Review

Faithward Advisors reduced its Halozyme (HALO) stake by 60% in Q2 2026, selling an estimated $2.6M and leaving 25,249 shares worth $1.98M. The position accounts for 0.24% of the portfolio, ranked #104.

Faithward Advisors first reported a position in HALO in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.24M in Q1 2026. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Faithward Advisors held 25,249 shares of Halozyme worth $1.98M as of Q2 2026.
  • Faithward Advisors sold 38,154 Halozyme shares in Q2 2026, an estimated $2.6M.
  • Halozyme made up 0.24% of Faithward Advisors's portfolio in Q2 2026, its #104 holding.
  • Faithward Advisors first reported a position in Halozyme in Q4 2025 and has held it in 3 quarters since.
  • Faithward Advisors's Halozyme position peaked at $5.24M in Q1 2026.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Faithward Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.